enzalutamide sold brand name xtandi nonsteroidal antiandrogen nsaa medication used treatment prostate indicated use conjunction castration treatment metastatic castrationresistant prostate cancer nonmetastatic castrationresistant prostate metastatic castrationsensitive prostate cancer taken side effects enzalutamide added castration include asthenia back pain diarrhea arthralgia hot rarely cause high potential drug enzalutamide antiandrogen acts antagonist androgen receptor biological target androgens like testosterone prevents effects hormones prostate gland elsewhere enzalutamide first described introduced treatment prostate cancer first secondgeneration nsaa world health organizations list essential good evidence enzalutamide effective treatment increasing overall survival among people highrisk nonmetastatic castrationresistant prostate cancer particularly psa doubling time enzalutamide used antiandrogen feminizing hormone therapy transgender enzalutamide provided form mg taken orally dosage mg per day four enzalutamide contraindicated women may cause fetal notable side effects enzalutamide seen clinical trials included gynecomastia breast paintenderness fatigue diarrhea hot flashes headache sexual dysfunction less commonly common side effects reported clinical trials included neutropenia visual hallucinations anxiety cognitive disorder memory impairment hypertension dry skin pruritus enzalutamide monotherapy regarded moderate negative effect sexual function activity significantly less gnrh analogues similar nsaas seizures occurred approximately patients treated enzalutamide clinical thought due enzalutamide crossing exerting offtarget binding inhibition gabaa receptor central nervous system found inhibit gabaa receptor vitro halfmaximal inhibitory concentration induces convulsions animals high addition seizures potentially gabaa receptorrelated side effects observed enzalutamide treatment clinical trials included anxiety insomnia vertigo paresthesia due ability lower seizure threshold patients known seizure disorders brain injury closely monitored enzalutamide nsaainduced seizures responsive benzodiazepine treatment suggested gabaa receptor inhibition enzalutamide could treated doseranging studies severe fatigue observed enzalutamide doses mgday single case report posterior reversible encephalopathy syndrome pres enzalutamide mechanism action side effect unknown proposed consequence inhibition gabaa receptor enzalutamide may cause seizures enzalutamide moderate strong inducer multiple cytochrome enzymes including hence high potential clinically relevant drug circulating concentrations enzalutamide may altered inhibitors inducers avoided clinical study enzalutamide ertooltip estrogen receptorpositive breast cancer women enzalutamide found decrease serum concentrations aromatase inhibitors anastrozole exemestane respectively could reduce enzalutamide acts selective silent antagonist androgen receptor ar biological target androgens like testosterone dihydrotestosterone dht unlike firstgeneration nsaa bicalutamide enzalutamide promote translocation ar cell nucleus addition prevents binding ar deoxyribonucleic acid dna ar coactivator described ar signaling inhibitor addition drug described secondgeneration nsaa greatly increased efficacy antiandrogen relative socalled firstgeneration nsaas like flutamide bicalutamide drug lower affinity ar dht endogenous ligand ar prostate lncap cells prostate cancer cell line engineered express elevated levels ar found patients advanced prostate cancer treated enzalutamide expression androgendependent genes psa regulated contrast bicalutamide expression vcap cells overexpress ar enzalutamide induced apoptosis whereas bicalutamide furthermore enzalutamide behaves antagonist mutant ar contrast bicalutamide behaves pure agonist bound doseranging studies enzalutamide men prostate cancer enzalutamide monotherapy dosage mgday found increase circulating levels testosterone dihydrotestosterone dht estradiol sex hormonebinding globulin shbg dehydroepiandrosterone dhea androstenedione luteinizing hormone lh folliclestimulating hormone fsh prolactin changes hormone levels similar highdose bicalutamide median maximum decrease levels prostatespecific antigen psa levels enzalutamide approximately higher binding affinity androgen receptor ar compared one study found halfmaximal inhibitory concentration nm enzalutamide nm bicalutamide ar lncap cell line another found respective values nm nm accordance clinical findings suggest enzalutamide significantly potent effective antiandrogen comparison firstgeneration nsaas bicalutamide flutamide also unlike firstgeneration nsaas evidence hepatotoxicity elevated liver enzymes association enzalutamide treatment clinical enzalutamide effective certain period time growth cancer inhibited antiandrogen mechanisms resistance enzalutamide intensively currently several mechanisms found enzalutamide reported strong inducer enzyme moderate inducer affect circulating concentrations drugs metabolized bioavailability enzalutamide humans unknown least based amount recovered urine bile excretion similarly bioavailability enzalutamide rats steadystate concentrations enzalutamide achieved within days treatment plasma protein binding enzalutamide ndesmethylenzalutamide ndme major metabolite enzalutamide primarily bound medication metabolized liver mainly cytochrome enzymes primarily responsible formation enzalutamide long elimination halflife days average range elimination halflife ndme even longer enzalutamide eliminated urine bile enzalutamide synthetic diaryl thiohydantoin derivative structurally related earlier firstgeneration nsaas flutamide nilutamide bicalutamide well newer secondgeneration nsaas like apalutamide enzalutamide discovered charles sawyers memorial cancer michael jung university california los colleagues synthesized evaluated nearly thiohydantoin derivatives analogue nilutamide ar antagonism human prostate cancer cells identified enzalutamide lead compounds patented described enzalutamide developed marketed medivation treatment prostate approved us food drug administration fda treatment mcrpc united states august treatment nonmetastatic castrationresistant prostate cancer july enzalutamide first new ar antagonist approved treatment prostate cancer years following introduction firstgeneration nsaa bicalutamide first secondgeneration nsaa research suggests enzalutamide may effective treatment certain types breast cancer tested treatment triplenegative arpositive breast cancer phase ii clinical enzalutamide suggested potential treatment hirsutism hyperandrogenism women polycystic ovary httpsenwikipediaorgwikienzalutamide